Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Single-Blind Study to Assess Efficacy and Safety of Dosing Mesalazine 800 mg Tablets (Asacol®) at 2.4 g Once Daily Versus Divided Doses 3 Times Daily for 12 Months in Maintenance of Remission of Ulcerative Colitis.

NCT00708656 is registered in ClinicalTrials.gov with Cardiff and Vale University Health Board as lead sponsor.

NCT NCT00708656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00708656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Single-Blind Study to Assess Efficacy and Safety of Dosing Mesalazine 800 mg Tablets (Asacol®) at 2.4 g Once Daily Versus Divided Doses 3 Times Daily for 12 Months in Maintenance of Remission of Ulcerative Colitis.
Lead sponsor
Cardiff and Vale University Health Board
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2006
Completion date
September 30, 2010
Enrollment
213 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis